Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was the recipient of a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 234,700 shares, agrowthof134.5% from the June 30th total of 100,100 shares. Based on an average trading volume of 719,200 shares, the days-to-cover ratio is presently 0.3 days. Based on an average trading volume of 719,200 shares, the days-to-cover ratio is presently 0.3 days.

Bayer Aktiengesellschaft Stock Up 1.5%

OTCMKTS BAYRY traded up $0.11 during trading on Friday, reaching $7.51. 526,748 shares of the company's stock were exchanged, compared to its average volume of 818,785. The company's fifty day simple moving average is $7.82 and its 200-day simple moving average is $6.72. Bayer Aktiengesellschaft has a fifty-two week low of $4.79 and a fifty-two week high of $8.65. The firm has a market capitalization of $29.51 billion, a PE ratio of -7.74 and a beta of 0.91. The company has a current ratio of 1.25, a quick ratio of 0.79 and a debt-to-equity ratio of 1.07.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.10. Bayer Aktiengesellschaft had a positive return on equity of 15.48% and a negative net margin of 7.61%. The business had revenue of $12.42 billion during the quarter, compared to analyst estimates of $10.79 billion. Sell-side analysts predict that Bayer Aktiengesellschaft will post 1.31 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on BAYRY shares. Kepler Capital Markets upgraded Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research report on Wednesday, June 11th. Wall Street Zen lowered shares of Bayer Aktiengesellschaft from a "buy" rating to a "hold" rating in a research report on Saturday, July 26th. The Goldman Sachs Group upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research report on Thursday, June 5th. Finally, Hsbc Global Res raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, June 11th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Bayer Aktiengesellschaft has a consensus rating of "Buy".

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.